Torren Management’s Lifecore Biomedical LFCR Stock Holding History

Torren Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,312	Closed	-$18.9K	–	1235
2025 Q4	$18.9K	Buy	+2,312	New	+$17.1K	0.01%	592

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Torren Management's LFCR Position: Q1 2026 in Review

Torren Management sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 2,312 shares — an estimated $18.9K sold.

Torren Management first reported a position in LFCR in Q4 2025 and held it in 1 quarter. The position peaked at $18.9K in Q4 2025. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

Torren Management reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
Torren Management sold 2,312 Lifecore Biomedical shares in Q1 2026, an estimated $18.9K.
Torren Management first reported a position in Lifecore Biomedical in Q4 2025 and held it in 1 quarter.
Torren Management's Lifecore Biomedical position peaked at $18.9K in Q4 2025.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.